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Introduction
Scaling up antiretroviral therapy (ART) in sub-Saharan 
Africa represents a major achievement, but there are 
ongoing challenges, including increasing transmitted 
drug resistance,1 poor coverage of viral load monitoring,2 
and low numbers of people who have fulfilled the criteria 
for failure of first-line ART switching to second-line 
regimens.3
Until recently, WHO recommended a sequence of 
first-line tenofovir, lamivudine (or emtricitabine), and 
efavirenz and second-line zidovudine, lamivudine, and a 
protease inhibitor in people with first-line failure.4 
However, WHO now recommends use of the integrase 
inhibitor dolutegravir with tenofovir and lamivudine in 
people initiating ART and, potentially, in those currently 
on first-line ART if they have a recent viral load 
measurement less than 1000 copies per mL.5 In people 
with virological failure on tenofovir, lamivudine, and 
efavirenz, dolutegravir in the context of an optimised 
nucleoside reverse transcriptase inhibitor background is 
recommended as a second-line regimen, which most 
often will be zidovudine, lamivudine, and dolutegravir. 
Dolutegravir-based regimens are associated with less need 
to switch to other antiretroviral drugs and there is a lower 
risk of development of major drug resistance mutations 
compared with efavirenz-based regimens.6,7 Dolutegravir 
therapy also has superior outcomes compared with a 
boosted protease inhibitor-based regimen in people 
starting second-line therapy with at least one active 
nucleoside reverse transcriptase inhibitor.8 An alternative 
to this approach to dolutegravir use would be to transition 
all people on ART to tenofovir, lamivudine, and 
dolutegravir, unless or until there is sustained virological 
failure, at which point zidovudine, lamivudine, and a 
protease inhibitor would be used. Since access to viral load 
testing is difficult in many countries, this approach has 
the potential to bring greater public health benefits. 
However, these benefits should be balanced against 
concerns over a possible risk of increased resistance to 
dolutegravir and other drugs. Modelling can help policy 
makers think through the balance of these considerations 
in the context of a public health approach.
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Summary
Background The integrase inhibitor dolutegravir could have a major role in future antiretroviral therapy (ART) 
regimens in sub-Saharan Africa because of its high potency and barrier to resistance, good tolerability, and low cost, 
but there is uncertainty over appropriate policies for use relating to the potential for drug resistance spread and a 
possible increased risk of neural tube defects in infants if used in women at the time of conception. We used an 
existing individual-based model of HIV transmission, progression, and the effect of ART with the aim of informing 
policy makers on approaches to the use of dolutegravir that are likely to lead to the highest population health gains.
Methods We used an existing individual-based model of HIV transmission and progression in adults, which takes 
into account the effects of drug resistance and differential drug potency in determining viral suppression and clinical 
outcomes to compare predicted outcomes of alternative ART regimen policies. We calculated disability adjusted 
life-years (DALYs) for each policy, assuming that a woman having a child with a neural tube defect incurs an extra 
DALY per year for the remainder of the time horizon and accounting for mother-to-child transmission. We used a 
20 year time horizon, a 3% discount rate, and a cost-effectiveness threshold of US$500 per DALY averted.
Findings The greatest number of DALYs is predicted to be averted with use of a policy in which tenofovir, lamivudine, 
and dolutegravir is used in all people on ART, including switching to tenofovir, lamivudine, and dolutegravir in those 
currently on ART, regardless of current viral load suppression and intention to have (more) children. This result was 
consistent in several sensitivity analyses. We predict that this policy would be cost-saving.
Interpretation Using a standard DALY framework to compare health outcomes from a public health perspective, 
the benefits of transition to tenofovir, lamivudine, and dolutegravir for all substantially outweighed the risks.
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Furthermore, dolutegravir could be a cause of neural 
tube defects in the children of a small proportion of 
women taking dolutegravir at the time of conception—
in a 2018 report,9 four incidences of neural tube defects 
occurred in 596 pregnancies, which is above the back-
ground expected for efavirenz-based therapy regimens. 
This finding has raised questions over the use of 
dolutegravir in women of child bearing age. However, 
restriction of dolutegravir use in women of child 
bearing age has a public health cost that policy makers 
should weigh against the possible neural tube defect 
risk.
In this study, we used an existing individual-based 
model of HIV transmission, progression, and the effect 
of ART to help inform policy makers on approaches to 
the use of dolutegravir that are likely to lead to the highest 
population health gains. We aimed to provide quantitative 
assessment of the risks and benefits of alternative 
policies for use of dolutegravir to inform ministries of 
health in their policy decision making in consultation 
with the communities they serve.
Methods 
Model description
In this modelling study, we used the HIV Synthesis 
Model (for full details see appendix).10 Briefly, this model 
(programmed in SAS version 9.4) generates a population 
who are individually tracked, with updates every 
3 months, for risk of HIV acquisition. Those who acquire 
HIV are tracked in terms of their viral load, CD4 cell 
count, occurrence of WHO stage 3 and 4 conditions, use 
of specific drugs, presence of resistance mutations, 
adherence, and drug toxicities. The ongoing effects of a 
drug regimen (on viral load, drug resistance, and 
CD4 count, and hence risk of AIDS and death) are 
dependent on the sum of the activity of each drug in the 
regimen, accounting for presence of drug resistance 
mutations, drug potency, and level of adherence. This 
study was not submitted for ethics committee review as it 
does not involve research on human subjects.
Setting scenarios
The model is based on sub-Saharan Africa, with 
1000 potential setting scenarios generated through 
simulation. We randomly varied parameters, including 
the rate of HIV testing, distribution of ART adherence 
across individuals, the rate of ART interruption, number 
of switches to a second-line regimen after failure of a 
first-line regimen (detected by confirmed viral load 
above 1000 copies per mL), and the ability to measure 
viral load as indicated,11 within plausible bounds for 
settings in the region. For a complete list of parameters 
see the appendix (p 27).
For each setting scenario, we considered the situation 
in 2018 and compared outcomes of potential regimen 
policies over a 20 year time horizon (50 years in sensitivity 
analysis). The regimen policies considered are described 
in table 1. Our reference regimen policy was a con-
tinuation of the approach of use of tenofovir, lamivudine, 
and efavirenz in first-line regimens. We also considered 
four further policies, involving use of tenofovir, 
lamivudine, and dolutegravir. These policies consider 
tenofovir, lamivudine, and dolutegravir use with or 
without dependence on intention to have (more) children 
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Research in context
Evidence before this study
The integrase inhibitor dolutegravir is expected to have a role 
in future antiretroviral therapy (ART) regimens in sub-Saharan 
Africa because of its high potency and barriers to resistance, 
good tolerability, and low cost. However, which policy for use 
of dolutegravir will produce the greatest population health 
benefits is unclear because of considerations over the potential 
for virological failure and drug resistance spread if used with 
nucleoside reverse transcriptase inhibitors to which HIV is 
resistant, and a possible association between dolutegravir and 
an increased risk of neural tube defects in infants if used at 
conception in women. We searched Web of Knowledge using 
the terms “dolutegravir” and “model*” on Aug 14, 2018, 
with no date or language restrictions, and identified 74 papers. 
When we reviewed these papers we did not identify any that 
used modelling to quantify the risks and benefits of different 
policies for introduction of dolutegravir in sub-Saharan Africa.
Added value of this study
We used an existing individual-based model of HIV 
transmission and progression in adults to compare predicted 
outcomes of alternative regimen policies. The model takes into 
account the effects of drug resistance and potency in 
determining viral load and clinical treatment outcomes, 
and the effect of a potentially increased risk of neural tube 
defects in infants if dolutegravir is taken by women at 
conception. We considered policies of using a regimen 
containing tenofovir, lamivudine, and dolutegravir for all 
individuals on ART, or of making tenofovir, lamivudine, 
and dolutegravir dependent on viral load suppression (whether 
on first-line or second-line ART) or, for women, intention to 
have (more) children.
Implications of all the available evidence
Using a standard disability adjusted life-year framework for 
comparing health outcomes from a public health perspective, 
we found that the benefits of transition to a regimen of 
tenofovir, lamivudine, and dolutegravir for all people on ART, 
without dependence on viral suppression or intention to have 
(more) children, substantially outweighed the risks. 
Our evaluation provides quantitative assessment to guide 
policy formulation by ministries of health on the use of 
dolutegravir.
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or current viral load suppression being docu mented. The 
rationale for restriction of use of tenofovir, lamivudine, 
and dolutegravir to those with viral sup pression is due to 
concern that resistance to tenofovir and lamivudine is 
likely to have developed in those with virological failure, 
making dolutegravir the only fully active drug and 
meaning the risk of resistance to dolutegravir is increased. 
The extent of any residual effects on viral replication due 
to continued exposure to lamivudine and tenofovir in 
these circumstances is uncertain.12,13 Policies involving 
tenofovir, lamivudine, and dolutegravir depending on 
viral suppression also involve use of zidovudine rather 
than tenofovir in newly initiated second-line regimens. 
This approach is broadly consistent with current WHO 
interim guidance.5 We refer throughout this Article to use 
of lamivudine in regimens, but emtricitabine might be 
used instead. Dependence on a woman’s intention to have 
(more) children relates to concern over the risk of neural 
tube defects if dolutegravir is used at the time of 
conception. Policies with this dependence are envisaged 
to offer dolutegravir to women only upon reaching the 
point of intention to have no more children. We assume a 
rate of reaching a point of intention to have no more 
children to be 0·005 per 3 months from age 25 years. This 
rate results in 16% of women aged 15–55 years not 
intending to have (more) children, which is consistent 
with data from Demographic and Health Surveys.14,15 We 
assume that women who intend to have no more children 
are able to access and use contra ception, and that 
contraceptive efficacy is 80% (50% in sensitivity analysis). 
We refer to the policy for which tenofovir, lamivudine, and 
dolutegravir use is dependent on neither viral suppression 
nor intention to have more children as tenofovir, 
lamivudine, and dolutegravir for all.
Assumptions for resistance acquisition with 
dolutegravir-containing regimens are informed by data 
on the risk of resistance mutations existing at virological 
failure and studies of monotherapy, which were mainly 
done in people with existing viral suppression but 
include a small study of dolutegravir monotherapy in 
ART-naive people with viral loads less than 100 000 copies 
per mL.6,7,16–22 We inferred a 13 times lower rate of 
Men and women not intending to have (more) children Women intending to have (more) children
New 
initiators
Currently on 
first-line 
tenofovir, 
lamivudine, 
and efavirenz
Currently on 
second-line 
zidovudine, 
lamivudine, 
and protease 
inhibitor 
(atazanavir)
At future 
tenofovir, 
lamivudine, 
and efavirenz 
failure
At future 
tenofovir, 
lamivudine, 
and dolutegravir 
failure
New 
initiators
Currently on 
first-line 
tenofovir, 
lamivudine, 
and efavirenz
Currently on 
second-line 
zidovudine, 
lamivudine, 
and protease 
inhibitor 
(atazanavir)
At future 
tenofovir, 
lamivudine, 
and efavirenz 
failure
At future 
tenofovir, 
lamivudine, 
and 
dolutegravir 
failure
Tenofovir, 
lamivudine, and 
efavirenz for all
Tenofovir, 
lamivudine, 
and efavirenz
Tenofovir, 
lamivudine, 
and efavirenz
Zidovudine, 
lamivudine, 
and protease 
inhibitor 
(atazanavir)
Zidovudine, 
lamivudine, 
and protease 
inhibitor 
(atazanavir)
·· Tenofovir, 
lamivudine, 
and efavirenz
Tenofovir, 
lamivudine, 
and efavirenz
Zidovudine, 
lamivudine, 
and protease 
inhibitor 
(atazanavir)
Zidovudine, 
lamivudine, 
and protease 
inhibitor 
(atazanavir)
··
Tenofovir, 
lamivudine, and 
dolutegravir 
dependent on viral 
suppression and 
intention to have 
(more) children
Tenofovir, 
lamivudine, 
and 
dolutegravir
Switch to 
tenofovir, 
lamivudine, 
and dolutegravir 
if viral load 
<1000 copies 
per mL
Switch to 
tenofovir, 
lamivudine, 
and dolutegravir 
if viral load 
<1000 copies 
per mL
Zidovudine, 
lamivudine, 
and 
dolutegravir
Zidovudine, 
lamivudine, 
and protease 
inhibitor 
(atazanavir)
Tenofovir, 
lamivudine, 
and efavirenz
Tenofovir, 
lamivudine, 
and efavirenz
Zidovudine, 
lamivudine, 
and protease 
inhibitor 
(atazanavir)
Zidovudine, 
lamivudine, 
and protease 
inhibitor 
(atazanavir)
··
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
intention to have 
(more) children 
only
Tenofovir, 
lamivudine, 
and 
dolutegravir
Switch to 
tenofovir, 
lamivudine, and 
dolutegravir
Switch to 
tenofovir, 
lamivudine, 
and dolutegravir
·· Zidovudine, 
lamivudine, 
and protease 
inhibitor 
(atazanavir)
Tenofovir, 
lamivudine, 
and efavirenz
Tenofovir, 
lamivudine, 
and efavirenz
Zidovudine, 
lamivudine, 
and protease 
inhibitor 
(atazanavir)
Zidovudine, 
lamivudine, 
and protease 
inhibitor 
(atazanavir)
··
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on viral 
suppression only
Tenofovir, 
lamivudine, 
and 
dolutegravir
Switch to 
tenofovir, 
lamivudine, 
and dolutegravir 
if viral load 
<1000 copies 
per mL
Switch to 
tenofovir, 
lamivudine, 
and dolutegravir 
if viral load 
<1000 copies 
per mL
Zidovudine, 
lamivudine, 
and 
dolutegravir
Zidovudine, 
lamivudine, 
and protease 
inhibitor 
(atazanavir)
Tenofovir, 
lamivudine, 
and 
dolutegravir
Switch to 
tenofovir, 
lamivudine, 
and dolutegravir 
if viral load 
<1000 copies 
per mL
Switch to 
tenofovir, 
lamivudine, 
and dolutegravir 
if viral load 
<1000 copies 
per mL
Zidovudine, 
lamivudine, 
and 
dolutegravir
Zidovudine, 
lamivudine, 
and protease 
inhibitor 
(atazanavir)
Tenofovir, 
lamivudine, 
and dolutegravir 
for all
Tenofovir, 
lamivudine, 
and 
dolutegravir
Switch to 
tenofovir, 
lamivudine, 
and dolutegravir
Switch to 
tenofovir, 
lamivudine, 
and dolutegravir
·· Zidovudine, 
lamivudine, 
and protease 
inhibitor 
(atazanavir)
Tenofovir, 
lamivudine, 
and 
dolutegravir
Switch to 
tenofovir, 
lamivudine, 
and dolutegravir
Switch to 
tenofovir, 
lamivudine, 
and dolutegravir
·· Zidovudine, 
lamivudine, 
and protease 
inhibitor 
(atazanavir)
Table 1: Description of regimen policies considered
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resistance to dolutegravir than to efavirenz. Dolutegravir 
is generally associated with a lower risk of toxicity than 
are efavirenz and protease inhibitors, resulting in 
reduced discontinuation.6,16,19,23 We assumed that the risk 
of neurological toxicity with dolutegravir was half that 
for efavirenz, and assumed that dolutegravir has 
1·5 times higher potency than does efavirenz (lower 
than boosted protease inhibitors, which were assumed 
to have potency of 2), consistent with its effect as a 
monotherapy17 (although insufficient for its clinical use 
as monotherapy). We assumed that the residual effects 
of tenofovir in the presence of the Lys65Arg mutation 
and lamivudine in the presence of the Met184Val 
mutation mean that they each have 0·25 times full drug 
activity in this situation.12,13 We present our main results 
as the mean and mean difference compared with the 
policy of tenofovir, lamivudine, and efavirenz for all, 
with a 90% range reflecting variation across setting 
scenarios and 95% CI reflecting stochastic simulation 
variability.
Although these assumptions formed our base assump-
tions, we considered the possibility of different assump-
tions for dolutegravir in a proportion of our 1000 setting 
scenarios. These proportions for alternative assumptions 
were selected on the basis of the perceived probability that 
they hold. Thus, we considered that potency of dolutegravir 
could be 1 (20% of setting scenarios), 1·25 (20% of setting 
scenarios), or 2 times (5% of setting scenarios) that of 
efavirenz, instead of 1·5 times (55% of setting scenarios); 
that development of resistance to dolutegravir could be 
only 3 times lower than for efavirenz (20% of setting 
scenarios); that the risk of neurological toxicity using 
dolutegravir could be equal to that of efavirenz (20% of 
setting scenarios); and that the residual effects of tenofovir 
and lamivudine in the presence of the Lys65Arg and 
Met184Val mutations was 0·0 rather than the 0·25 of a fully 
active drug (20% of setting scenarios in each case). We also 
considered different degrees to which viral load monitoring 
was implemented (25% of setting scenarios each for prob-
abilities of 0·0, 0·10, 0·25, and 0·85 of a viral load test 
being done, and the result delivered in accordance with the 
recommended monitoring strategy) and ART regimen was 
switched after viral failure was determined (probabilities of 
0·05 in 30% of setting scenarios, 0·20 in 50% of setting 
scenarios, and 0·50 in 20% of setting scenarios per 
3 months). We determined these alternative assumptions 
by random independent sampling for each setting scenario. 
Full details of the distribution of all sampled parameters 
used in deriving our 1000 setting scenarios are shown in 
the appendix (p 27). Excess risk of neural tube defects in 
babies of women on dolutegravir at the time of conception 
was assumed to be 0·58% (4 in 596=0·67% minus the 
0·09% background rate in HIV-negative women); we did 
sensitivity analyses using values of 1% and 3%.
The range of HIV epidemic and programmatic char-
acteristics in 2018 for our 1000 setting scenarios are 
shown in table 2 with comparable observed data.
Model outcomes
Our primary measure of health outcome was disability 
adjusted life-years (DALYs). Although we explicitly 
modelled the individual life courses of adults only, we 
considered DALY effects of neural tube defects and 
of mother-to-child HIV transmission. We estimated the 
aggregate effects that alternative policies have on popu-
lation burden of disease by calculating net DALYs, which 
are the DALYs averted by a policy minus the health 
opportunity costs imposed as a result of costs incurred. 
Health opportunity costs are calculated using country 
cost-effectiveness thresholds, which represent the health 
gains that could be generated by alternative uses of 
resources.28 Country-specific thresholds are uncertain but 
US$500 averted per DALY is likely to be at the upper end 
on the basis of evidence concerning how resources would 
otherwise be used,29 and we used this value. We calculated 
net DALYs as DALYs plus costs divided by the cost-
effectiveness threshold. Absolute numbers of health-
related events, costs, DALYs, and net DALYs that we report 
are relevant for a country with a population size of around 
10 million adults in 2018. We did our analysis from 
Model (2018)* Examples of observed data
HIV prevalence (age 15–49 years) 10% (5–19) Zimbabwe 2016 14%, Tanzania 2017 5%, 
Uganda 2017 6%, Lesotho 2017 24%, 
Swaziland 2017 27%, Malawi 2016 10%†
HIV incidence age 15–49 years 
(per 100 person-years)
0·8 (0·3–1·6) Malawi 2016 0·37, Zambia 2016 0·66, 
Zimbabwe 2016 0·45, Lesotho 2017 1·55, 
Namibia 2016 0·40, Swaziland 2017 1·48, 
Tanzania 2017 0·27†
Proportion of HIV-positive people 
diagnosed
83% (69–93) Malawi 2016 73%, Zambia 2016 67%, 
Zimbabwe 2016 74%, Namibia 2017 86%, 
Tanzania 2017 52%† (see also Kim and 
colleagues,24 which suggests undisclosed 
diagnosed HIV)
Proportion of all HIV-positive people 
with viral load <1000 copies per mL
57% (31–71) Zambia 2016 60%, Malawi 2016 68%, 
Zimbabwe 2016 60%, Swaziland 2017 73%, 
Lesotho 2017 68%, Tanzania 2017 52%, 
Uganda 2017 60%, Cameroon 2017 45%, 
Namibia 2017 77%†
Proportion of ART-experienced 
people who have started second-line 
(boosted protease inhibitors) therapy
2·4% (0·5–9·4) Malawi 1·5%25
Of people on ART, proportion with 
viral load <1000 copies per mL
85% (74–91) Zambia 2016 89%, Malawi 2016 91%, 
Zimbabwe 2016 87%, Cameroon 2017 80%, 
Namibia 2017 91%, Tanzania 2017 88%, 
Uganda 2017 84%†
Percentage of ART-naive ART 
initiators with non-nucleoside 
reverse-transcriptase inhibitor 
resistance
11% (2–29) Angola 2012 14%, Botswana 2016 8%, 
South Africa 2017 14%, Zimbabwe 2015 10%, 
Namibia 2015 9%, Cameroon 2015 8%, 
Uganda 2016 16%26
Mother-to-child transmission 
proportion
3·7% (1·9–6·7) All 2014: Botswana 2% within 6 weeks, 4% final; 
South Africa 1% within 6 weeks, 4% final; 
Namibia 1% within 6 weeks, 7% final; Uganda 2% 
within 6 weeks, 8% final; Zimbabwe 5% within 
6 weeks, 12% final; Malawi 7% within 6 weeks, 
7% final; Angola 10% within 6 weeks, 25% final27
Values represent 1000 setting scenarios for people aged 15–64 years, unless otherwise stated. ART=antiretroviral 
therapy. *Values are median (90% range). †Data from Population Health Impact Survey.
Table 2: HIV epidemic and programmatic characteristics of setting scenarios in 2018
For Population Health Impact 
Survey data see https://phia.
icap.columbia.edu/
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Tenofovir, 
lamivudine, 
and 
efavirenz 
for all
Tenofovir, lamivudine, 
and dolutegravir dependent on 
viral suppression and intention to 
have (more) children
Tenofovir, lamivudine, 
and dolutegravir dependent on 
intention to have (more) 
children only
Tenofovir, lamivudine, 
and dolutegravir dependent on 
viral suppression only
Tenofovir, lamivudine, 
and dolutegravir for all
Proportion on efavirenz 92% 52%; 
−40% (−41 to −39; −52 to –22)
42%; −50% 
(−51% to −49; −61 to −39)
15%; −77% 
(−78 to −76; −92 to −47)
0%; −92% 
(−93 to −91; −100 to −78)
Proportion on dolutegravir 0% 43%; 43% (42 to 44; 22 to 57) 54%; 54% (53 to 55; 42 to 63) 85%; 83% (82 to 85; 47 to 97) 98%; 98% (97 to 99; 94 to 100)
Proportion on atazanavir 8% 5%; −3% (−4 to −2; –9 to 0) 4%; –3% (–4 to –2; –9 to –1) 2%; –6% 
(–7 to –5; –16% to 0)
2%; –6% (–7 to –5; –16 to 0)
Proportion on zidovudine* 8% 5%; –2% (–3 to –1; –8 to 0) 4%; –4% (–5 to –3; –10 to –2) 4%; –4% (–5 to –3; –13 to 0) 2%; –6% (–7 to –5 ;–16 to 0)
Proportion of people on ART with viral load <1000 copies per mL
Mean over 1 year 84% 85%; 0% (0 to 0; 0 to 2) 87%; 2% (2 to 2; 0 to 5) 85%; 1% (1 to 1; –1 to 3) 90%; 6% (6 to 6; 1 to 11)
Mean over 5 years 84% 86%; 2% (2 to 2; 0 to 4) 87%; 3% (3 to 3; 0 to 7) 88%; 4% (4 to 4; 1 to 8) 91%; 7% (7 to 7; 1 to 14)
Mean over 20 years 82% 87%; 5% (5 to 5; 1 to 9) 87%; 5% (5 to 5; 1 to 11) 91%; 9% (9 to 9; 3 to 16) 91%; 10% (10 to 10; 2 to 18)
Of people with baseline viral load >1000 copies per mL and Lys65Arg and Met184Val mutations at baseline, percentage of people on ART with viral load <1000 copies per mL
Mean over 1 year 7% 9%; 3% (2 to 4; –1 to 8) 23%; 16% (15 to 17; 4 to 28) 14%; 7% (6 to 8; –1 to 21) 49%; 42% (40 to 44; 15 to 64)
Mean over 5 years 22% 26%; 4% 
(3 to 5%; –1 to 10)
35%; 13% 
(12 to 14; –3 to 32)
33%; 11% 
(9 to 13; –1 to 25)
55%; 32% 
(29 to 35; –3 to 72%)
Mean over 20 years 50% 50%; 0% (–1 to 1; –9 to 8) 52%; 2% (–1 to 5; –16 to 46) 53%; 3% (1 to 5; –15 to 18) 57%; 7% (3 to 11; –22 to 64)
AIDS death rate in people on 
ART (per 100 person-years)
1·70 1·25; –0·46 
(–0·48 to –0·44; –0·94 to –0·12)
1·08; –0·63 
(–0·66 to –0·60; –1·34 to –0·14)
0·94; –0·76 
(–0·79 to –0·73; –1·51 to –0·24)
0·72; –0·98 
(–1·02 to –0·94; –2·02 to –0·24)
AIDS death rate in people 
on ART with viral load 
>1000 copies per mL 
(per 100 person-years)
7·05 6·29; –0·76 
(–0·82 to –0·70; –1·41 to –0·12)
5·71; –1·34 
(–1·44 to –1·24; –2·54 to –0·45)
5·92; –1·12 
(–1·22 to –1·02; –2·22 to –0·14)
4·77; –2·28 
(–2·08 to –2·48; –4·36 to –0·48)
AIDS death rate in people 
on ART with viral load 
>1000 copies per mL and 
CD4 count <200 cells per µL 
(per 100 person-years)
18·07 17·22; –0·85 
(–1·24 to –0·66; –2·01 to 0·91)
16·05; –2·02 
(–2·26 to 1·78; –4·15 to –0·11)
17·05; –1·03 
(–1·34 to –0·72; –3·41 to 1·45)
14·77; –3·30  
(–3·78 to –2·82; –8·43 to 0·03)
Proportion of all 
HIV-positive people with 
a dolutegravir resistance 
mutation
0% 2·6%; 2·6% 
(2·3 to 2·7; 0·4 to 7·7)
4·0%; 4·0% 
 (3·8 to 4·2; 0·6 to 11·0)
4·4%; 4·4% 
(4·1 to 4·7; 0·7 to 12·9)
6·7%; 6·7%  
(6·2 to 7·0; 1·2 to 18·5)
Proportion of all 
HIV-positive people with 
an efavirenz resistance 
mutation
28% 22%; –6% 
(–6 to –6; –12 to –1)
20%; –8% 
(–8 to –8; –14 to –3)
15%; –13% 
(–13 to –13; –22 to –6)
13%; –15% 
(–15 to 15; –24 to –8)
Adverse birth outcomes among women with HIV (percentage of pregnancies)
Mother-to-child 
transmission
4·2% 3·9%; –0·2% 
(–0·2 to –0·2; –0·8 to 0·3)
3·8%; –0·3% 
(–0·3 to –0·3; –1·1 to 0·3)
2·9%; –1·2% 
(–1·2 to –1·2; –2·5 to –0·3)
2·8%; –1·4 
(–1·4 to –1·4; –2·9 to –0·3)
Neural tube defect 
due to dolutegravir†
0% 0·02%; 0·02% 
(0·02 to 0·02; 0·0 to 0·08)
0·03%; 0·03% 
(0·03 to 0·03; 0·0 to 0·09%)
0·52%; 0·52% 
(0·49 to 0·55; –0·12 to 1·38)
0·60%; 0·60%  
(0·58 to 0·62; 0·15 to 1·51)
Costs‡ (annual difference 
compared with tenofovir, 
lamivudine, and efavirenz)§
·· –$5·3 million 
(–$5·8 million to –$4·8 million; 
–$19·6 million to $2·0 million)
–$5·3 million 
(–$4·8 million to –$5·8 million; 
–$20·4 million to $3·1 million)
–$10·5 million 
(–$11·3 million to $9·7 million; 
–$37·4 million to $1·4 million)
–$9·7 million 
(–$10·6 million to –$8·8 million; 
–$38·0 million to $3·9 million)
DALYs averted‡ (per year, 
compared with tenofovir, 
lamivudine, and efavirenz)¶
·· 22 300  
(21 300 to 23 300;  
1400 to 53 000)
32 800 
(31 300 to 34 300;  
3900 to 78 200)
39 500 
 (37 000 to 42 000;  
7900 to 87 900)
58 200  
(55 700 to 61 300;  
11 500 to 138 300)
Incremental 
cost-effectiveness ratio||
Dominated Dominated Dominated Reference $44
Net DALYs (per year, 
compared with tenofovir, 
lamivudine, and efavirenz)¶
·· 32 900 (31 400 to 34 400;  
2700 to 84 200)
43 500 (41 700 to 45 300;  
8600 to 103 100)
60 600 (58 000 to 63 200;  
11 800 to 143 400)
77 700 (74 700 to 80 700;  
20 800 to 177 600)
Data are mean proportion and mean difference (95% CI; 90% range reflecting variation across setting scenarios) compared with the policy of tenofovir, lamivudine, and efavirenz for all, unless otherwise indicated. DALYs 
and net DALYs were measured over 20 years (2018–38) and represent the mean over 3 month periods, unless otherwise stated. Costs are in US$. ART=antiretrovoral therapy. DALY=disability adjusted life-year. *As 
opposed to tenofovir disoproxil fumarate, all are on lamivudine. †Neural tube defects potentially caused by dolutegravir if possible signal is confirmed. ‡In the context of an adult population of 10 million people with HIV 
prevalence as in table 2. Costs and DALYs are discounted at 3% per annum. §Values are mean and mean difference (95% CI; 90% range reflecting variation across setting scenarios). ¶Values are n per year (95% CI; 
90% range reflecting variation across setting scenarios). ||Policies are dominated if there is another policy with both lower cost and more DALYs averted. The reference policy is selected among non-dominated policies.
Table 3: Predicted effect of regimen policies on intermediate outcomes, DALYs, and net DALYs
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a health-care perspective. We discounted future costs and 
health outcomes to present values of 3% per annum. 
We assumed the costs of tenofovir, lamivudine, and 
dolutegravir and tenofovir, lamivudine, and efavirenz to 
be US$75 per year, and the cost of zidovudine, lamivudine, 
and a protease inhibitor (atazanavir) to be $265.30 Full 
details of unit costs and disability weights are provided in 
the appendix (p 33).
For a woman having a baby with a neural tube defect, an 
extra DALY was incurred for each subsequent year of the 
20 year time horizon since the baby is assumed to die 
(ie, years lost from a child’s life were valued the same as 
years lost from an adult’s life). We assumed no monetary 
costs as a result of neural tube defects, except in a sensitivity 
analysis. Depending on an HIV-positive woman’s viral 
load, birth of an HIV-infected child can occur. We assumed 
that an HIV-infected child will access ART and that an 
additional 0·1 DALYs, and cost of $160 per year are incurred 
for each subsequent year of the 20 year time horizon.
Role of the funding source
The funder of the study had no role in study design, 
modelling approach, interpretation, or writing of the 
report.  The corresponding author had full access to all 
model programs and outputs in the study and had final 
responsibility for the decision to submit for publication.
Results
Consequences of the various regimen policies for the use 
of each drug are shown in table 3. A mean of 98% of 
people receiving ART over 20 years would be expected 
to be on dolutegravir with the policy of tenofovir, 
lamivudine, and dolutegravir for all, compared with 
only 43% if its use was dependent on viral load sup-
pression and being male or a woman not intending to 
have (more) children.
The predicted effect on viral load suppression is shown 
in people on ART over a mean of 1 year, 5 years, and 
20 years (table 3). Restriction of tenofovir, lamivudine, 
and dolutegravir use in women who intend to have 
(more) children was predicted to lead to poorer overall 
viral suppression over 1 year, 5 year, and 20 year time 
periods. Dependence of use of tenofovir, lamivudine, and 
dolutegravir on viral load suppression was predicted to 
lead to reduced overall viral suppression over 1 year and 
5 year time periods, although we found little difference 
in viral suppression over the 20 year time period. 
Restriction of analysis to the subgroup of people with 
viral loads greater than 1000 copies per mL and presence 
of drug mutations to tenofovir and lamivudine at baseline 
revealed a markedly higher predicted proportion of 
people with viral load suppression over the 1 year time 
period for the policy of tenofovir, lamivudine, and 
dolutegravir for all compared with the other policies, 
because with this policy a switch was made to tenofovir, 
lamivudine, and dolutegravir and with the dependence 
on viral suppression policies no switch was made. This 
difference persisted with longer follow-up durations but 
was less marked because of identification of virological 
failure and switching to zidovudine, lamivudine, and 
dolutegravir or zidovudine, lamivudine, and a protease 
inhibitor occurs with the policy of tenofovir, lamivudine, 
and dolutegravir dependent on viral suppression. Since 
this subgroup has a tendency for poorer adherence, and 
with our assumptions about resistance to dolutegravir 
and the residual activity of tenofovir and lamivudine, 
the percentage of patients with viral sup pression was 
predicted to remain at less than 60% with all policies, 
including tenofovir, lamivudine, and dolutegravir for all. 
Use of tenofovir, lamivudine, and dolutegravir was 
predicted to lead to more future dolutegravir resistance 
com pared with tenofovir, lamivudine, and dolutegravir 
dependent on viral sup pression (mean 6·7%, 90% range 
across setting scenarios 1·2–18·5 vs 4·4%, 0·7–12·9% in 
the context of no dependence on intention to have more 
children; table 3). In the final year of the 20 year time 
horizon, the corresponding figures were 9·4% (1·6–26·3) 
and 7·6% (1·4–21·3; data not shown).
The number of deaths due to AIDS in people on ART 
showed a similar pattern to overall viral suppression 
over the 1 year and 5 year time horizons, with AIDS 
deaths declining with increasing use of tenofovir, 
lamivudine, and dolutegravir, and at their lowest for the 
policy of tenofovir, lamivudine, and dolutegravir for all 
(table 3). Differences between policies in people on 
ART with viral load suppression translate into sub-
stantial differences in AIDS deaths because of the high 
death rate in those without viral suppression at any 
point in time. The lower death rate in those without 
viral suppression in the tenofovir, lamivudine, and 
dolutegravir for all policy is due to a lower CD4 count, 
even within the CD4 count less than 200 cells per µL 
range.
Figure: Overall health benefit (DALYs averted) and increment in cost 
compared with tenofovir, lamivudine, and efavirenz for all 
Values are the mean over 3 month periods of 1000 setting scenarios during 
20 year time periods, expressed per year. DALY=disability adjusted life-year.
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DALYs averted (per year)
Tenofovir, 
lamivudine, and 
efavirenz for all
Tenofovir, lamivudine, and 
dolutegravir dependent on  intention 
to have (more) children only
Tenofovir, 
lamivudine, and 
dolutegravir 
dependent on viral 
suppression and 
intention to have 
(more) children
Tenofovir, lamivudine, and 
dolutegravir dependent on 
viral suppression only
Tenofovir, 
lamivudine, and 
dolutegravir for 
all
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DALYs averted Net DALYs averted (% of setting scenarios in which policy is the most 
cost-effective*)
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
viral suppression 
and intention to 
have (more) 
children
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
intention to have 
(more) children 
only
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
viral suppression 
only
Tenofovir, 
lamivudine, 
and dolutegravir 
for all
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
viral suppression 
and intention to 
have (more) 
children
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
intention to have 
(more) children 
only
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
viral suppression 
only
Tenofovir, 
lamivudine, 
and dolutegravir 
for all
No restriction (base case) 22 300 
(21 300 to 23 300; 
1400 to 53 000)
32 800 
(31 300 to 34 300; 
3900 to 78 200)
39 500 
(37 000 to 42 000; 
7900 to 87 900)
58 200 
(55 700 to 61 300; 
11 500 to 138 300)
32 900 (<1%) 
(31 400 to 34 400; 
2700 to 84 200)
43 500 (1%) 
(41 700 to 45 300; 
8600 to 103 100)
60 600 (16%) 
(58 000 to 63 200; 
11 800 to 
143 400)
77 700 (83%) 
(74 700 to 80 700; 
20 800 to 
177 600)
Restrictions to setting scenarios
Development of 
resistance to 
dolutegravir is 3 times 
higher
20 300 
(18 100 to 22 500; 
0 to 50 400)
29 100 
(25 800 to 32 400; 
3000 to 72 800)
35 800 
(32 400 to 39 200; 
8900 to 81 400)
50 100 
(44 700 to 55 500; 
4800 to 124 500)
29 700 (0%) 
(26 700 to 32 700; 
3400 to 72 800)
38 300 (1%) 
(34 700 to 41 900; 
9200 to 88 800)
54 400 (24%) 
(49 400 to 59 400; 
11 900 to 127 200)
66 600 (75%) 
(50 900 to 72300; 
21 000 to 
149 100)
Toxicity to dolutegravir 
the same as efavirenz
21 800 
(19 600 to 24000; 
2800 to 52 300)
31 600 
(28 400 to 34 800; 
3200 to 73 500)
38 800 
(35 200 to 42 400; 
6600 to 87 900)
58 400 
(52 800 to 64 000; 
11 800 to 131 100)
32 100 (1%) 
(28 600 to 35 600; 
3000 to 84 100)
41 800 (1%) 
(37 800 to 45 800; 
9300 to 91 700)
59 100 (16%) 
(53 300 to 64 900; 
9800 to 141 900)
76 600 (82%) 
(69 900 to 83 300; 
19 500 to 
167 400)
Potency of dolutegravir 
1·0 (equal to efavirenz)
16 900 
(15 200 to 18 600; 
–1000 to 40 600)
23 700 
(21 100 to 26 300; 
–100 to 53 900)
30 200 
(27 500 to 32 900; 
4400 to 62 900)
41 900 
(37 800 to 46 000; 
2200 to 93 900)
24 000 (1%) 
(21 500 to 26 500; 
900 to 52 500)
30 900 (1%) 
(28 100 to 33 700; 
6500 to 63 600)
45 400 (31%) 
(41 300 to 49 500; 
9600 to 95 000)
54 600 (68%) 
(50 200 to 59 000; 
17 700 to 108 800
Potency of dolutegravir 
1·0 (equal to efavirenz) 
plus development of 
resistance to 
dolutegravir 3 times 
higher
13 700 
(10 300 to 17 100; 
–2600 to 33 500)
18 600 
(13 700 to 23 500; 
–1300 to 53 800)
25 300 
(19 800 to 30 800; 
4000 to 57 100)
32 000 
(23 600 to 40 400; 
1000 to 91 000)
19 100 (0%) 
(15 100 to 23 100; 
–1300 to 41 000)
23 100 (3%) 
(18 700 to 27 500; 
3300 to 47 700)
35 600 (49%) 
(29 800 to 41 400; 
9200 to 72 000)
39 100 (49%) 
(31 900 to 46 300; 
4900 to 84 500)
Pre-ART 
non-nucleoside 
reverse-transcriptase 
inhibitor resistance 
in 2018 >10%
27 900 
(26 40 to 29 400; 
5100 to 61 400)
40 400 
(38 100 to 42 700; 
8600 to 93 800)
48 800 
(46 300 to 51 300; 
12 800 to 
104 700)
71 100 
(67 700 to 75 100; 
19 300 to 157 300)
41 500 (0%) 
(39 100 to 43 900; 
7300 to 97 200)
54 200 (<1%) 
(51 500 to 56 900; 
14 200 to 118 000)
76 100 (14%) 
(72 100 to 80 100; 
21 700 to 172 000)
96 400 (86%) 
(92 000 to 
100 800; 34 500 
to 20 300)
Pre-ART 
non-nucleoside 
reverse-transcriptase 
inhibitor resistance 
in 2018 <5%
12 700 
(11 200 to 14 200; 
–2500 to 34 400)
20 100 
(17 900 to 22 300; 
–300 to 51 900)
23 400 
(21 300 to 23 500; 
1500 to 51 100)
36 100 
(32 400 to 39 800; 
3800 to 87 000)
18 200 (1%) 
(16 200 to 20 200; 
300 to 42 700)
25 600 (2%) 
(23 100 to 28 100; 
2800 to 59 400)
34 600 (21%) 
(31 500 to 37 700; 
6000 to 72 200)
46 400 (76%) 
(42 500 to 50 300; 
13 700 to 106 700)
Zero residual activity of 
tenofovir and 
lamivudine in the 
presence of Lys65Arg or 
Met184Val mutations
26 600 
(20 900 to 32 300; 
2500 to 67 900)
35 300 
(27 300 to 43 300; 
5300 to 94 800)
46 700 
(37 500 to 55 900; 
6300 to 109 500)
62 700 
(49 400 to 76 000; 
10 500 to 
168 200)
37 600 (0%) 
(29 400 to 45 800; 
2500 to 98 500)
45 000 (0%) 
(35 800 to 54 200; 
5800 to 108 500)
68 300 (26%) 
(54 300 to 82 300; 
18 400 to 
172 100)
80 500 (74%) 
(64 800 to 
96 200; 20 290 to 
198 394)
Rate of switch after 
virological failure 0·05 
per 3 months
25 000 
(23 000 to 27 000; 
1700 to 57 900)
37 200 
(34 300 to 40 100; 
5400 to 85 600)
44 900 
(41 700 to 48 100; 
10 400 to 101 700)
65 700 
(61 100 to 70 300; 
18 300 to 145 000)
31 400 (<1%) 
(28 600 to 34 200; 
300 to 78 500)
42 800 (1%) 
(39 500 to 46 100; 
6500 to 103 600)
58 500 (14%) 
(54 000 to 
63 000; 12 400 to 
135 800)
76 500 (84%) 
(71 100 to 81 900; 
19 500 to 
178 100)
Rate of switch after 
virological failure 0·5 
per 3 months
17 100 
(15 400 to 19 800; 
–600 to 38 700)
26 300 
(23 700 to 28 900; 
300 to 66 200)
31 500 
(28 700 to 34 300; 
4400 to 63 300)
46 900 
(41 400 to 51 400; 
3800 to 111 200)
28 900 (<1%) 
(26 200 to 31 600; 
3100 to 72 700)
38 900 (1%) 
35 800 to 42 000; 
8800 to 81 800
54 400 (18%) 
(39 500 to 58 900; 
11 600 to 132 400)
69 200 (81%) 
(64 100 to 74 300; 
22 600 to 143 500
Proportion of women 
giving birth per 
3 month period >4%
24 700 
(22 000 to 27 400; 
2300 to 53 400)
36 600 
(32 500 to 40 700; 
2200 to 95 600)
43 500 
(41 300 to 47 700; 
12 700 to 91 200)
65 800 
(59 000 to 72 600; 
11 900 to 160 700)
35 000 (1%) 
(31 000 to 39 000; 
4900 to 89 700)
47 000 (0%) 
(42 400 to 51 600; 
11 500 to 106 400)
64 800 (11%) 
(58 400 to 71 200; 
18 000 to 
144 200)
85 400 (89%); 
77 600 to 93 200; 
19 800 to 
184 000)
Proportion of women 
giving birth per 
3 month period <4%
21 900 
(20 800 to 23 000; 
1400 to 52 600)
32 100 
(30 400 to 33 800; 
3900 to 75 900)
38 800 
(37 000 to 40 600; 
7000 to 87 800)
56 700 
(54 000 to 59 400; 
11 308 to 131 100)
32 500 (<1%) 
(30 700 to 34 300; 
2200 to 84 100)
42 800 (1%) 
(40 800 to 44 800; 
7800 to 97 100)
59 800 (17%) 
(56 900 to 63 700; 
10 800 to 
142 600)
76 100 (82%) 
(72 900 to 79 300; 
20 900 to 
168 000)
(Table 4 continues on next page)
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DALYs averted Net DALYs averted (% of setting scenarios in which policy is the most 
cost-effective*)
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
viral suppression 
and intention to 
have (more) 
children
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
intention to have 
(more) children 
only
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
viral suppression 
only
Tenofovir, 
lamivudine, 
and dolutegravir 
for all
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
viral suppression 
and intention to 
have (more) 
children
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
intention to have 
(more) children 
only
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
viral suppression 
only
Tenofovir, 
lamivudine, 
and dolutegravir 
for all
(Continued from previous page)
Risk of neural tube 
defects with 
dolutegravir 1·0%
22 300 
(21 300 to 23 300; 
1400 to 52 800)
32 800 
(31 300 to 34 300; 
3900 to 78 200)
38 600 
(37 000 to 40 200; 
7500 to 86 900
57 100 
(54 600 to 59 600; 
10 600 to 136 100)
32 900 (<1%) 
(31 300 to 34 500; 
2700 to 84 200)
43 400 (1%) 
(41 600 to 45 200; 
8600 to 102 900)
59 700 (16%) 
(57 100 to 62 300; 
11 600 to 141 700)
76 500 (84%) 
(75 000 to 78 000; 
20 300 to 175 500)
Risk of neural tube 
defects with 
dolutegravir 3·0%
22 100 
(21 100 to 23 100; 
1400 to 52 700)
32 500 
(31 000 to 34 000; 
3700 to 78 200)
34 300 
(32 800 to 35 800; 
4300 to 81 300)
51 600 
(49 100 to 54 100; 
5900 to 127 900)
32 700 (<1%) 
(31 200 to 34 200; 
2500 to 84 100)
43 200 (1%) 
(41 400 to 45 400; 
8600 to 102 000)
55 400 (16%) 
(52 900 to 57 900; 
9700 to 132 700)
71 000 (82%) 
(68 200 to 73 800; 
18 000 to 
166 800)
Viral load testing fully 
implemented
19 100 
(17 300 to 20 900; 
800 to 43 000)
21 000 
(18 900 to 23 100; 
–1700 to 48 500)
32 800 
(30 000 to 35 600; 
6700 to 66 800)
36 200 
(32 800 to 39 600; 
2500 to 77 500)
40 700 (0%) 
(37 200 to 44 200; 
8400 to 92 300)
44 100 (2%) 
(40 300 to 47 900; 
9600 to 98 200)
72 800 (28%) 
(66 900 to 78 700; 
23 600 to 
150 500)
78 200 (70%) 
(71 900 to 84 500; 
23 900 to 173 600)
Viral load testing not 
implemented
19 100 
(17 200 to 21 000; 
–2500 to 44 400)
43 800 
(40 100 to 47 000; 
7700 to 96 500)
34 800 
(31 800 to 37 800; 
2900 to 76 100)
79 300 
(73 400 to 85 200; 
21 600 to 159 100)
18 300 (0%) 
(16 300 to 20 300; 
–2800 to 44 600)
41 400 (0%) 
(37 800 to 45 000; 
5600 to 88 500)
35 700 (3%) 
(32 500 to 37 900; 
1200 to 82 500)
75 000 (98%) 
(69 200 to 80 800; 
18 300 to 152 800)
Higher background 
treatment interruption
20 900 
(18 900 to 22 900; 
–300 to 51 300)
29 900 
(27 100 to 32 700; 
3000 to 76 400)
39 000 
(35 900 to 42 100; 
10 200 to 89 100)
56 100 
(51 500 to 60 700; 
15 700 to 128 000
27 100 (0%) 
(24 300 to 29 900; 
500 to 72 900)
36 100 (1%) 
(32 800 to 39 400; 
3500 86 400)
52 300 (16%) 
(47 700 to 56 900; 
9800 to 127 700)
67 500 (83%) 
(62 000 to 73 000; 
16 700 to 151 200)
HIV prevalence (age 
15–49 years) in 2018 
<8%
12 700 
(11 500 to 13 900; 
–1900 to 29 100)
19 200 
(17 700 to 20 700; 
3000 to 40 500)
22 800 
(21 100 to 24 500; 
2000 to 50 800)
33 500 
(31 200 to 35 800; 
7000 to 65 400)
17 900 (1%) 
(16 200 to 19 600; 
–1300 to 40 100)
24 400 (2%) 
(22 600 to 26 200; 
3500 to 52 100)
32 900 (22%) 
(30 300 to 35 500; 
3200 to 69 000)
42 600 (76%) 
(40 000 to 45 200; 
14 000 to 81 100)
HIV prevalence (age 
15–49 years) in 2018 
>12%
32 200 
(30 200 to 34 200; 
7900 to 68 400)
47 100 
(44 100 to 50 100; 
10 800 to 101 400)
56 300 
(53 300 to 59 300; 
17 100 to 114 000)
83 700 
(78 800 to 88 600; 
23 000 to 171 900)
48 400 (0%) 
(45 400 to 51 400; 
12 000 to 103 000)
63 400 (<1%) 
(60 100 to 66 700; 
21 900 to 121 200)
89 300 (10%) 
(84 400 to 94 200; 
30 100 to 
184 100)
114 500 (90%) 
(109 300 to 
119 700; 45 900 to 
209 200)
HIV incidence (age 
15–49 years) in 2018 
(per 100 person-years) 
<0·6
12 800 
(11 600 to 14 000; 
–1600 to 28 600)
20 000 
(18 200 to 21 800; 
1700 to 43 800)
22 000 
(20 300 to 23 700; 
2900 to 45 700)
34 400 
(31 700 to 37 100; 
6900 to 69 000)
19 400 (0%) 
(17 600 to 21 200; 
–1000 to 42 100
26 600 (<1%) 
(24 600 to 28 600; 
6400 to 55 200)
33 900 (20%) 
(31 200 to 36 600; 
3200 to 67 200)
45 300 (78%) 
(42 300 to 48 300; 
17 600 to 83 900)
HIV incidence (age 
15–49 years) in 2018 
(per 100 person-years) 
>1
30 800 
(28 800 to 32 800; 
5100 to 68 400)
44 600 
(41 600 to 47 600; 
8600 to 99 500)
55 400 
(52 300 to 58 500; 
16 600 to 
114 000)
81 000 
(76 200 to 85 800; 
21 900 to 167 500)
45 000 (0%) 
(42 000 to 48 000; 
8300 to 100 200)
58 900 (0%) 
(55 500 to 62 300; 
13 800 to 121 000)
84 900 (12%) 
(79 900 to 89 900; 
26 800 to 
181 900)
108 000 (88%) 
(102 500 to 
113 500; 36 500 to 
208 500)
Proportion of 
HIV-positive people 
diagnosed in 2018 
<75%
17 700 
(15 600 to 19 800; 
200 to 41 500)
25 200 
(22 400 to 28 000; 
3000 to 56 200)
36 200 
(32 700 to 39 700; 
6300 to 74 200)
49 800 
(44 800 to 54 800; 
11 900 to 111 900)
22 900 (0%) 
(20 000 to 25 800; 
500 to 58 400)
30 300 (1%) 
(26 900 to 33 700; 
3900 to 68 300)
47 900 (21%) 
(42 400 to 52 900; 
8200 to 120 000)
59 900 (78%) 
(54 100 to 65 700; 
17 600 to 130 200)
Proportion of HIV 
positive people 
diagnosed in 2018 
>88%
25 400 
(23 300 to 27 500; 
2000 to 59 900)
37 800 
(34 500 to 41 100; 
5000 to 93 800)
42 300 
(38 900 to 45 700; 
8300 to 103 700)
64 700 
(61 400 to 70 000; 
16 000 to 152 000)
39 700 (0%) 
(36 100 to 43 300; 
5300 to 98 400)
52 000 (0%) 
(48 100 to 55 900; 
10 400 to 118 900)
68 400 (11%) 
(62 700 to 74 100; 
11 100 to 162 200)
88 900 (89%) 
(82 600 to 95 200; 
25 900 to 200 500)
Proportion of 
ART-experienced 
people who started 
second-line (boosted 
protease inhibitor) 
ART in 2018 <1·5%
19 900 
(17 900 to 21 900; 
–300 to 47 000)
34 200 
(31 300 to 37 100; 
5000 to 75 900)
38 200 
(35 200 to 41 200; 
8200 to 82 900)
63 300 
(58 700 to 67 900; 
16 700 to 134 900)
21 300 (<1%) 
(19 100 to 23 500; 
–1500 to 55 900)
34 700 (1%) 
(31 700 to 37 700; 
2600 to 79 600)
42  700 (11%) 
(39 000 to 46 400; 
6200 to 101 800)
64 300 (88%) 
(59 500 to 70 100; 
14 900 to 136 300)
Proportion of 
ART-experienced 
people who started 
second-line (boosted 
protease inhibitor) ART 
in 2018 >4%
20 600 
(18 800 to 22 400; 
1200 to 47 000)
23 900 
(21 700 to 26 100; 
–1300 to 54 600)
34 800 
(32 100 to 36 500; 
6400 to 75 500)
39 600 
(36 100 to 43 100; 
3200 to 93 600)
44 900 (0%) 
(41 700 to 48 100; 
12 100 to 98 800)
49 800 (1%) 
(46 300 to 53 300; 
11 600 to 107 700)
80 100 (27%) 
(74 800 to 85 400; 
26 100 to 162 700)
86 500 (72%) 
(82 600 to 92 400; 
26 800 to 185 500)
(Table 4 continues on next page)
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DALYs averted Net DALYs averted (% of setting scenarios in which policy is the most 
cost-effective*)
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
viral suppression 
and intention to 
have (more) 
children
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
intention to have 
(more) children 
only
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
viral suppression 
only
Tenofovir, 
lamivudine, 
and dolutegravir 
for all
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
viral suppression 
and intention to 
have (more) 
children
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
intention to have 
(more) children 
only
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
viral suppression 
only
Tenofovir, 
lamivudine, 
and dolutegravir 
for all
(Continued from previous page)
Of people on ART, 
proportion with viral 
load <1000 copies per 
mL in 2018 <80%
32 800 
(29 600 to 36 000; 
10 400 to 74 000)
48 400 
(43 600 to 53 200; 
10 700 to 109 500)
59 000 
(54 000 to 64 000; 
17 400 to 129 500)
87 300 
(84 800 to 89 800; 
24 300 to 185 900)
40 900 (0%) 
(36 400 to 
45 400; 3800 to 
98 500)
55 400 (0%) 
(50 000 to 60 800; 
7400 to 122 900)
77 500 (11%) 
(70 900 to 87 100; 
18 200 to 185 700)
101 400 (89%) 
(98 400 to 
104 400; 31 000 
to 218 800)
Of people on ART, 
proportion with viral 
load <1000 copies 
per mL in 2018 >88%
13 700 
(12 400 to 15 000; 
–1600 to 30 900)
17 600 
(15 800 to 19 400; 
–1800 to 40 600)
23 600 
(21 600 to 25 600; 
1900 to 51 100)
30 000 
(27 200 to 32 800; 
1300 to 67 800)
27 300 (1%) 
(24 700 to 29 900; 
2200 to 61 300)
32 200 (2%) 
(29 500 to 34 900; 
6800 to 69 100)
48 900 (26%) 
(44 800 to 53 000; 
11 000 to 111 200)
56 100 (71%) 
(51 800 to 60 400; 
14 500 to 120 100)
Cost-effectiveness 
threshold US$200
22 300 
(21 300 to 23 300; 
1400 to 53 000)
32 800 
(31 300 to 34 300; 
3900 to 78 200)
39 500 
(37 000 to 42 000; 
7900 to 87 900)
58 200 
(55 700 to 61 300; 
11 500 to 138 300)
48 700 (<1%) 
(45 900 to 51 500; 
–100 to 107 200)
59 400 (1%) 
(56 500 to 62 300; 
8400 to 156 900)
92 300 (21%) 
(87 300 to 97 300; 
12 600 to 252 200)
106 900 (78%) 
(101 900 
to 111 900; 20 700 
to 270 100)
Cost-effectiveness 
threshold US$1000
22 300 
(21 300 to 23 300; 
1400 to 53 000)
32 800 (31 300 
to 34 300; 3900 
to 78 200)
39 500 (37 000 to 
42 000; 7900 to 
87 900)
58 200 (55 700 
to 61 300; 11 500 
to 138 300)
27 600 (<1%) 
26 300 to 28 900; 
3100 to 66 000
38 200 (1%) 
(36 600 to 39 800; 
7200 to 87 300)
50 100 (14%) 
(48 100 to 52 100; 
12 600 to 111 600)
67 900 (85%) 
(65 300 to 70 500; 
18 800 to 153 100)
Additional sensitivity analyses
Dolutegravir potency 
becomes 0·75 during 
tuberculosis treatment
21 700 
(18 700 to 24 700; 
4800 to 42 900)
31 300 
(26 300 to 36 300; 
2700 to 69 400)
38 600 
(33 800 to 43 400; 
6700 to 73 700)
55 300 
(47 100 to 63 500; 
13 500 to 122 600)
31 800 (0%) 
(27 500 to 36 100; 
5600 to 72 400)
41 500 (0%) 
(36 300 to 
46 700; 15 200 to 
85 700)
58·700 (15%) 
(51 800 to 
65 600; 16 200 to 
134 900)
74 900 (85%) 
(68 300 to 83 500; 
23 500 to 
158 700)
For policies with 
dependence on viral 
suppression, people on 
zidovudine, lamivudine, 
and protease inhibitor 
(atazanavir) are moved 
to zidovudine, 
lamivudine, and 
dolutegravir rather 
than tenofovir, 
lamivudine, and 
dolutegravir
23 100 
(20 800 to 25 400; 
1300 to 52 800)
33 000 
(29 600 to 36 400; 
6200 to 68 100)
40 800 
(37 100 to 44 500; 
10 400 to 83 700)
56 800 
(53 400 to 60 200; 
13 000 to 131 700)
33 900 (0%) 
(30 500 to 37 300; 
3900 to 81 200)
43 700 (0%) 
(39 900 to 47 500; 
11 400 to 90 000)
62 300 (20%) 
(66 600 
to 68 000; 14 400 
to 128 900)
76 900 (80%) 
(70 400 to 83 400; 
22 500 to 159 100)
Higher mother-to-
child transmission
20 000 
(18 000 to 22 000; 
1100 to 46 300)
29 700 
(26 700 to 32 700; 
2600 to 75 800)
36 400 
(33 400 to 39 400; 
5900 to 80 000)
54 000 
(49 200 to 54 800; 
9100 to 123 900)
30 800 (0%) 
(27 900 to 33 700; 
4500 to 68 900)
40 700 (0%) 
(37 400 to 44 000; 
9000 to 85 800)
58 300 (15%) 
(53 600 
to 63 000; 14 300 
to 119 800)
75 600 (85%) 
(70 100 to 81 100; 
23 600 to 160 800)
Defects not fatal in 
50% of babies born 
with neural tube 
defects and lifetime 
disability weight and 
cost incurred for 
surviving babies†
21 100 
(18 900 to 23 300; 
1400 to 50 200)
29 900 
(26 800 to 33 000; 
2000 to 67 500)
37 800 
(34 400 to 41 200; 
8800 to 79 600)
53 900 
(48 800 to 59 000; 
10 000 to 112 700)
32 900 (5%) 
(29 700 to 36 100; 
2500 to 73 300)
42 100 (18%) 
(38 500 to 45 700; 
6500 to 88 600)
60 900 (14%) 
(55 800 to 66 000; 
13 000 to 131 700)
76 000 (63%) 
(70 200 to 81 800; 
22 100 to 162 300)
Contraception has 
50% effectiveness 
instead of 80%
24 000 
(21 300 to 26 700; 
2600 to 54 900)
36 900 
(33 000 to 40 800; 
2700 to 87 700)
41 500 
(37 500 to 45 500; 
9400 to 89 600)
64 500 
(58 500 to 71 100; 
8400 to 142 700)
34 700 (1%) 
(30 700 to 38 700; 
5700 to 83 500)
47 300 (1%) 
(43 800 to 51 800; 
9600 to 105 800)
62 300 (19%) 
(56 000 to 68 600; 
14 700 to 137 900)
83 200 (80%) 
(75 800 to 90 600; 
19 300 to 178 400)
Efavirenz has potency 
1·5
20 200 
(17 400 to 23 000; 
–500 to 50 500)
28 300 
(24 100 to 32 400; 
0 to 84 600)
35 300 
(30 500 to 40 100; 
2700 to 91 000)
50 600 
(53 900 to 57 300; 
6800 to 132 200)
29 600 (1%) 
(25 600 to 33 600; 
4100 to 73 000)
38 100 (2%) 
(33 100 to 43 100; 
5100 to 98 900)
54 000 (15%) 
(47 300 to 60 700; 
12 800 to 133 700)
68 000 (82%) 
(60 400 to 75 600; 
19 200 to 158 500)
Viral load threshold 
50 copies per mL
18 100 
(15 000 to 21 200; 
–5200 to 48 600)
28 800 
(24 400 to 33 200; 
1200 to 69 000)
30 000 
(25 800 to 34 200; 
4800 to 66 600)
50 000 
(43 100 to 56 900; 
4800 to 108 000)
28 800 (0%) 
(24 100 to 33 500; 
–700 to 67 200)
40 300 (6%) 
(34 900 to 45 700; 
6800 to 80 800)
50 900 (9%) 
(43 800 to 58 000; 
6700 to 106 800)
68 100 (86%) 
(59 700 to 76 500; 
16 000 to 139 200)
(Table 4 continues on next page)
Downloaded for Anonymous User (n/a) at BS - University of Copenhagen from ClinicalKey.com by Elsevier on October 21, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
Articles
www.thelancet.com/hiv   Vol 6   February 2019 e125
The predicted proportion of HIV-positive women 
for whom mother-to-child transmission occurs also 
followed this pattern. The reduction in risk of mother-to-
child transmission with the tenofovir, lamivudine, and 
dolutegravir for all policy was greater in absolute terms 
than the increased risk of neural tube defects with the 
same policy (table 3).
There were substantially more DALYs averted with the 
tenofovir, lamivudine, and dolutegravir for all policy than 
for any of the policies in which tenofovir, lamivudine, 
and dolutegravir use was dependent on viral suppression 
or intention to have no (more) children. The lowest cost 
was for the tenofovir, lamivudine, and dolutegravir for all 
and tenofovir, lamivudine, and dolutegravir dependent 
on viral suppression only policies (figure). For net DALYs, 
the benefit of the tenofovir, lamivudine, and dolutegravir 
for all policy was greater still, reflecting the health gains 
elsewhere due to the lower costs, mainly because of 
reduced use of protease inhibitors, which are more than 
7 times the cost of dolutegravir. The policy of tenofovir, 
lamivudine, and dolutegravir for all was the most cost-
effective in 83% of setting scenarios, with tenofovir, 
lamivudine, and dolutegravir dependent on viral sup-
pression only the most cost-effective policy in 16% of 
setting scenarios. Tenofovir, lamivudine, and dolutegravir 
dependent on intention to have (more) children only was 
cost-effective in 1% of setting scenarios and tenofovir, 
lamivudine, and dolutegravir dependent on viral sup-
pression and intention to have (more) children was cost-
effective in less than 1% of setting scenarios (table 4). 
Tenofovir, lamivudine, and efavirenz for all was not cost-
effective in any setting scenario.
Tenofovir, lamivudine, and dolutegravir for all remained 
the most effective and cost-effective policy in several sensi-
tivity analyses (table 4).
DALYs averted Net DALYs averted (% of setting scenarios in which policy is the most 
cost-effective*)
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
viral suppression 
and intention to 
have (more) 
children
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
intention to have 
(more) children 
only
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
viral suppression 
only
Tenofovir, 
lamivudine, 
and dolutegravir 
for all
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
viral suppression 
and intention to 
have (more) 
children
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
intention to have 
(more) children 
only
Tenofovir, 
lamivudine, 
and dolutegravir 
dependent on 
viral suppression 
only
Tenofovir, 
lamivudine, 
and dolutegravir 
for all
(Continued from previous page)
Atazanavir resistance 
rate 3 times lower
22 600 
(18 600 to 26 600; 
4200 to 60 800)
33 100 
(26 600 to 39 600; 
7500 to 85 700)
37 500 
(31 900 to 43 300; 
7300 to 86 400)
56 600 
(46 400 to 66 800; 
17 000 to 128 000)
34 600 (0%) 
(28 200 to 41 000; 
6600 to 78 900)
45 700 (2%) 
(38 100 to 53 300; 
12 200 to 107 300)
60 400 (15%) 
(49 800 to 71 000; 
13 100 to 130 300)
78 200 (83%) 
(66 200 to 90 200; 
23 900 to 150 000)
50 year time horizon 49 000 
(41 800 to 56 200; 
700 to 136 000)
60 000 
(50 800 to 69 200; 
15 800 to 178 800)
84 200 
(72 800 to 95 600; 
9800 to 218 700)
93 200 
(79 500 
to 106 900; 
8800 to 269 300)
57 800 (0%) 
(50 400 to 65 200; 
1800 to 127 900)
69 100 (0%) 
(60 600 to 77 600; 
4200 to 161 500)
99 800 (0%) 
(88 600 
to 111 000; 15 600 
to 211 200)
107 200 (100%) 
(94 600 
to 119 800; 12 600 
to 242 200)
Values are DALYs and net DALYs averted compared with the policy of tenofovir, lamivudine, and efavirenz for all (95% CI; 90% range, reflecting variation across setting scenarios), unless otherwise indicated. 
DALY=disability adjusted life-year. ART=antiretroviral therapy. *Tenofovir, lamivudine, and efavirenz for all policy was the most cost-effective policy in 0% of all setting scenarios. †Disability weight for child living 
with neural tube defect is 0·5, cost is US$5000 in the first year (cost of surgery) and $1000 per year (cost of ongoing care and support) thereafter.
Table 4: Sensitivity analyses
Discussion
Supporting earlier work,31 we found that the benefits of a 
policy using tenofovir, lamivudine, and dolutegravir in 
people currently on first-line or second-line regimens, 
without any dependence on viral load or consideration of 
use of zidovudine rather than tenofovir, outweighed the 
risks. We also found that there were substantial net 
public health benefits of use of tenofovir, lamivudine, 
and dolutegravir, including in women of child bearing 
age, in terms of DALYs incurred in the whole population, 
and considering DALYs incurred as a result of birth of a 
child with a neural tube defect.
The benefits of the policy of tenofovir, lamivudine, and 
dolutegravir for all compared with tenofovir, lamivudine, 
and dolutegravir dependent on viral suppression are due 
to proactive use of dolutegravir without requiring a viral 
load measure or a switch algorithm to have been fulfilled. 
Even in the subgroup of people with viral load greater 
than 1000 copies per mL and presence of drug mutations 
to tenofovir and lamivudine at baseline, switching to 
tenofovir, lamivudine, and dolutegravir was predicted to 
bring benefits compared with the policies of tenofovir, 
lamivudine, and dolutegravir dependent on viral sup-
pression, as members of this subgroup must await 
fulfilment of the viral load failure criteria and subsequent 
switch to zidovudine, lamivudine, and dolutegravir. 
These benefits occur despite the fact that with the 
tenofovir, lamivudine, and dolutegravir for all policy, the 
proportion of people on ART with viral suppression over 
1 year, 5 years, and 20 years is predicted to be low 
(55% on average over 5 years) because of the higher 
tendency for poor adherence in this subgroup and the 
potential for dolutegravir resistance to emerge. Overall, 
dolutegravir resistance (transmitted or acquired) is 
predicted to be present in 6·7% of people over a 20 year 
Downloaded for Anonymous User (n/a) at BS - University of Copenhagen from ClinicalKey.com by Elsevier on October 21, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
Articles
e126 www.thelancet.com/hiv   Vol 6   February 2019
period under the policy of tenofovir, lamivudine, and 
dolutegravir for all compared with 4·4% under the policy 
of tenofovir, lamivudine, and dolutegravir dependent on 
viral sup pression only. Our findings were consistent in 
several sensitivity analyses, including one in which we 
assumed that lamivudine and tenofovir had no effect on 
viral replication in the presence of the Met184Val and 
Lys65Arg mutations, and one over a 50 year time 
horizon.
More children are predicted to be prevented from 
acquiring HIV through mother-to-child transmission 
than are born with neural tube defects with a tenofovir, 
lamivudine, and dolutegravir for all policy. When 
calculating DALYs in children born with HIV, we 
assumed availability of good HIV diagnosis and treat-
ment services in infants meaning less poor consequences 
for an HIV infection in a child (0·1 DALYs per year) than 
for a child born with a neural tube defect (1 DALY 
per year). Without such good availability of diagnosis and 
treatment services, the DALY consequences of a child 
born with HIV would be worse and the benefits of a 
policy of tenofovir, lamivudine, and dolutegravir for all 
greater.
Our study has limitations. As for any cost-effectiveness 
analysis over a long time horizon, we relied on a model 
for predictions of the long-term effect of the alternative 
policies. We made assumptions about the benefits and 
harms associated with different ART regimens on the 
basis of available data, which included different levels of 
uncertainty. The reports9 of neural tube defects in 
infants born to women using dolutegravir are the first 
indication of this risk and planned further follow-up of 
women who have been similarly exposed could reduce 
uncertainty over this risk. This situation emphasises 
that studies of novel drugs during the development 
phase and beyond—including in women before 
conception, during pregnancy, and postpartum—are 
crucial to support future decision making. Evidence of 
the anti retroviral effects of dolutegravir is more 
extensive, including recent data from a randomised trial 
in Cameroon.32 Our results are robust to modifications 
in assumptions within plausible levels of uncertainty, 
which supports our main conclusions. We recognise 
that our assumption that women can access 
contraception from the time of intention to have no 
(more) children does not reflect reality in many settings, 
and partly accounted for this by considering both 
an 80% and 50% effectiveness of contraception. We did 
not consider a policy option in which women could 
move between efavirenz and dolutegravir between 
pregnancies because we considered that this would be 
unrealistic to implement.
Our results could be used to inform relevant 
constituencies about the risks and benefits of alternative 
dolutegravir-containing ART regi men policy options, and 
to help gain an informed representative view from people 
with HIV that can be considered during development of 
ministry of health policies. If ministries of health decide 
to give dolutegravir to women who might become 
pregnant without adequate consultation and it then 
becomes clear that there is a real risk of neural tube 
defects, this could undermine confidence in treatment 
and in the ministry of health, although the extent to 
which ART uptake could be affected is difficult to quantify. 
However, we recognise that there will be substantial 
challenges in achieving such effective consultation.
In conclusion, the benefits of transition to tenofovir, 
lamivudine, and dolutegravir for all substantially out-
weighed any risks when using a standard DALY 
framework to compare health outcomes from a public 
health perspective.
Contributors
All authors conceptualised the analysis, had substantial input into the 
modelling plan and advised on relevant data, interpreted the results, 
and made comments on the manuscript drafts. AP, VC, FN, and LB-M 
wrote and executed the modelling program. ANP was the overall study 
lead.
Declaration of interests
DK is a consultant to ViiV Healthcare, Gilead Sciences, and Merck, 
and reports research funding from all three companies, and Janssen and 
AbbVie. JM reports grant support from the Bill & Melinda Gates 
Foundation, USAID, Brigham Women’s Hospital/AIDS Clinical Trials 
Group (ACTG) to the University of Pittsburgh Virology Support 
Laboratory, Janssen Pharmaceuticals, and Gilead Sciences, personal fees 
from University of Pittsburgh and Gilead Sciences, and share options in 
Co-Crystal Pharma, Inc. FV reports grants, personal fees and 
non-financial support from Viiv Healthcare and Gilead Sciences, 
personal fees and non-financial support from Mylan and Roche, 
personal fees from Adcock Ingram, Aspen Healthcare, J&J, and Merck, 
and grants from the Bill and Melinda Gates Foundation, Unitaid, 
USAID, and South African MRC, outside the submitted work. AP is a 
member of advisory boards for Gilead Sciences, ViiV Healthcare, Merck, 
and Jannsen, has spoken at non-commercial symposia funded by Gilead 
Sciences, ViiV Healthcare, Merck, and Jannsen, and is chair of the 
antiretrovirals section of the European AIDS Clinical Society guidelines. 
ADL reports research grants from ViiV Healthcare, Merck, and Gilead 
Sciences (Fellowship programme), and paid consultancies with ViiV 
Healthcare, Merck, Janssen, AbbVie, and Gilead Sciences. AW reports 
being on advisory boards for and grants from Janssen, Merck, Gilead 
Sciences, ViiV Healthcare, and CLJI. AC reports institutional 
unrestricted educational grants from ViiV Healthcare, AbbVie, BMS, 
MSD, and Gilead Sciences. All other authors declare no competing 
interests.
Data sharing
Model programs and simulations are accessible in Figshare.
Acknowledgments
We thank Elliot Raizes, Marco Vitoria, Nathan Ford, Meg Doherty, 
George Siberry, David Ripin, Lisa Nelson, Juliana da Silva, 
Carolyn Amole, Geoff Garnett, and Peter Ehrenkranz for their helpful 
advice. Our computing resource was legion@ucl. JDL is supported by 
Danish National Research Foundation. The findings and conclusions in 
this report are those of the authors and do not necessarily represent the 
official position of the authors’ institutions.
References
1 Gupta RK, Gregson J, Parkin N, et al. HIV-1 drug resistance before 
initiation or re-initiation of first-line antiretroviral therapy in 
low-income and middle-income countries: a systematic review and 
meta-regression analysis. Lancet Infect Dis 2018; 18: 346–55.
2 Medecins Sans Frontieres. Making viral load routine. Successes and 
challenges in the implementation of routine HIV viral load 
monitoring. 2016. https://www.msf.org/sites/msf.org/files/
making_viral_load_routine_part_1_programmatic_strategies.pdf 
(accessed Nov 1, 2018).
For more on Figshare see 
https://figshare.
com/s/2365d0eb9edd1e04294f
Downloaded for Anonymous User (n/a) at BS - University of Copenhagen from ClinicalKey.com by Elsevier on October 21, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
Articles
www.thelancet.com/hiv   Vol 6   February 2019 e127
3 Haas AD, Keiser O, Balestre E, et al. Monitoring and switching of 
first-line antiretroviral therapy in adult treatment cohorts in 
sub-Saharan Africa: collaborative analysis. Lancet HIV 2015; 
2: e271–78.
4 WHO. Consolidated guidelines on the use of antiretroviral drugs for 
treating and preventing HIV infection. Recommendations for a public 
health approach. 2nd edn. Geneva: World Health Organization, 2016.
5 WHO. Updated recommendations on first-line and second-line 
antiretroviral regimens and post-exposure prophylaxis and 
recommendations on early infant diagnosis of HIV. July, 2018. 
Geneva: World Health Organization, 2018.
6 Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus 
abacavir-lamivudine for the treatment of HIV-1 infection. 
N Engl J Med 2013; 369: 1807–18.
7 Wainberg MA, Han YS. Will drug resistance against dolutegravir in 
initial therapy ever occur? Front Pharmacol 2015; 6: 90.
8 Aboud M, Kaplan R, Lombaard J, et al. Superior efficacy of 
dolutegravir (DTG) plus 2 nucleoside reverse transcriptase 
inhibitors (NRTIs) compared with lopinavir/ritonavir (LPV/RTV) 
plus 2 NRTIs in second-line treatment: interim data from the 
DAWNING study. IAS 2017; Paris, France; July 23–16, 2017.
9 Zash R, Holmes L, Makhema J, et al. Surveillance for neural tube 
defects following antiretroviral exposure from conception. IAS 2018; 
Amsterdam, Netherlands; July 23–27, 2018.
10 Phillips AN, Cambiano V, Nakagawa F, et al. Cost-effectiveness of 
public-health policy options in the presence of pretreatment NNRTI 
drug resistance in sub-Saharan Africa: a modelling study. 
Lancet HIV 2018; 5: e146–54.
11 Philips A, Shroufi A, Vojnov L, et al. Sustainable HIV treatment in 
Africa through viral-load-informed differentiated care. Nature 2015; 
528: S68–76.
12 Xu HT, Martinez-Cajas JL, Ntemgwa ML, et al. Effects of the K65R 
and K65R/M184V reverse transcriptase mutations in subtype C HIV 
on enzyme function and drug resistance. Retrovirology 2009; 6: 14.
13 Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in 
HIV-1-infected patients harbouring a lamivudine-resistant virus: 
a randomized pilot study (E-184V study). AIDS 2006; 20: 795–803.
14 Zimbabwe National Statistics Agency, The DHS Program, ICF 
International. Zimbabwe Demographic and Health Survey 2015: 
Key Indicators. May, 2016. Rockville, MD: Zimbabwe National 
Statistics Agency (ZIMSTAT) and ICF International, 2016.
15 National Statistical Office Malawi, The DHS Program ICF. 
Malawi Demographic and Health Survey 2015–16. Zomba and 
Rockville, MD: National Statistical Office Malawi and ICF 
International, 2017.
16 Walmsley S, Baumgarten A, Berenguer J, et al. Brief report: 
dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 
infection in antiretroviral therapy-naive patients: week 96 and 
week 144 results from the SINGLE randomized clinical trial. 
J Acquir Immune Defic Syndr 2015; 70: 515–19.
17 Lanzafame M, Gibellini D, Lattuada E, et al. Dolutegravir 
monotherapy in HIV-infected naive patients with <100 000 copies/mL 
HIV RNA load. J Antimicrob Chemother 2016; 72: e12–14.
18 van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir 
(S/GSK1349572) in combination therapy in antiretroviral-naive 
adults with HIV: planned interim 48 week results from SPRING-1, 
a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012; 
12: 111–18.
19 Braun DL, Turk T, Hampel B, et al. Simplification to dolutegravir 
monotherapy is non-inferior compared to continuation of 
combination antiretroviral therapy in patients who initiated 
combination antiretroviral therapy during primary HIV infection: 
a randomized, controlled, non-inferiority trial. IAS 2018; 
Amsterdam, Netherlands; July 23–27, 2018.
20 Hocqueloux L, Allavena C, Prazuck T, et al. Dolutegravir monotherapy 
versus dolutegravir/abacavir/lamivudine for HIV-1-infected 
virologically suppressed patients: results from the randomized 
non-inferiority MONCAY trial. IAS 2018; Amsterdam, Netherlands; 
July 23–27, 2018.
21 Marcellin A, Grude G, Charpentier C, et al. French survey, 
resistance to integrase inhibitors shows differences of resistance 
selection in virological failure in care. HIV Glasgow 2016; Glasgow, 
Scotland; Oct 23–26, 2016. Abstr 332.
22 Bacheler LT, Anton ED, Kudish P, et al. Human immunodeficiency 
virus type 1 mutations selected in patients failing efavirenz 
combination therapy. Antimicrob Agents Chemother 2000; 
44: 2475–84.
23 Cuzin L. Integrase inhibitors and neuropsychiatric adverse events 
in a large prospective cohort. IAS 2018; Amsterdam, Netherlands; 
July 23–27, 2018.
24 Kim AA, Mukui I, Young PW, et al. Undisclosed HIV infection and 
antiretroviral therapy use in the Kenya AIDS indicator survey 2012: 
relevance to national targets for HIV diagnosis and treatment. 
AIDS 2016, 30: 2685–95.
25 Ministry of Health, Malawi, HIV/AIDS Department. Quarterly 
Reports. https://www.hiv.health.gov.mw/cha_repository/file.
php/186/186.pdf (accessed Nov 23, 2018).
26 WHO, CDC, The Global Fund. HIV drug resistance report 2017. 
Geneva: World Health Organization, 2017.
27 UNAIDS. 2015 progress report on the Global Plan towards the 
elimination of new HIV infections among children and keeping 
their mothers alive. Geneva: Joint United Nations Programme on 
HIV/AIDS, 2015. http://www.unaids.org/sites/default/files/media_
asset/JC2774_2015ProgressReport_GlobalPlan_en.pdf (accessed 
Nov 1, 2018).
28 Claxton K, Walker S, Palmer S, Sculpher M. Appropriate perspectives 
for health care decisions. Centre for Health Economics, University of 
York. 2010. https://ideas.repec.org/p/chy/respap/54cherp.html 
(accessed Nov 1, 2018).
29 Woods B, Revill P, Sculpher M, Claxton K. Country-level 
cost-effectiveness thresholds: initial estimates and the need for 
further research. March, 2015. https://www.york.ac.uk/media/che/
documents/papers/researchpapers/CHERP109_cost-effectiveness_
threshold_LMICs.pdf (accessed Nov 1, 2018).
30 The Global Fund. Pooled procurement mechanism reference 
pricing. July 2, 2018. https://www.theglobalfund.org/media/5813/
ppm_arvreferencepricing_table_en.pdf (accessed Nov 1, 2018).
31 Phillips A, Venter F, Apollo T, et al Cost-effectiveness of the 
introduction of dolutegravir in first or second-line ART regimens in 
sub-Saharan Africa. IAS 2017; Paris, France; July 23–16, 2017.
32 Cournil A, Kouanfack C, Eymard-Duvernay S, et al. Dolutegravir-
versus an efavirenz 400 mg-based regimen for the initial treatment 
of HIV-infected patients in Cameroon: 48-week efficacy results of 
the NAMSAL ANRS 12313 trial HIV Glasgow 2018; Glasgow, 
Scotland; Oct 28–31, 2018. Abstr O342.
Downloaded for Anonymous User (n/a) at BS - University of Copenhagen from ClinicalKey.com by Elsevier on October 21, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
